The rupee ended mildly higher yesterday amid ranged movement. The currency may sustain gains as a sharp decline in crude prices may provide some cushion to increased risks of spiralling deficit The USD was sharply higher as US a
Related Best And Worst ETFs Of The Week Amid Greek Relief Deal
With the Guggenheim CurrencyShares Japanese (NYSE: FXY) up 10.5 percent year-to-date, ranking it as one of the best-performing developed markets currency exchange-traded funds, it's not surprising that....More>>>
OppenheimerFunds Inc. increased its holdings in Silicon Laboratories (NASDAQ:SLAB) by 8.7% in the first quarter, HoldingsChannel reports. The institutional investor owned 302,063 shares of the semiconductor company’s stock after purchasing an additional 24,207 shares during the quarter. OppenheimerFunds Inc.’s holdings in Silicon Laboratories were worth $27,155,000 as of its most recent....More>>>
Berkshire Hathaway’s recent decision to scoop up another 75 million shares of Apple shows yet again Hathaway already held 165.3 million shares that Apple is one of the few tech companies that fits into Warren Buffett’s investment philosophy.
Buffett’s investment model has many components, of course, but Apple almost alone among big tech companies fits it well.
Tech stocks have had a huge run throughout the bull market with the Technology Select Sector SPDR (NYSE: XLF) surging 280% since March 2009. That’s well above the 226% gain in the broader S&P 500 and helped lift the market to price multiples rarely seen in the past.
Gains in the sector tracked the broader market closely until June 2016 when tech exploded, beating the index by 23%....More>>>
Headlines about Immersion (NASDAQ:IMMR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Immersion earned....More>>>
News stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned....More>>>
It's one of the few constants in the financial markets… Popular investment ideas are usually losers. As we often preach, it pays to be a contrarian. Or as billionaire investor Warren Buffett has famously said, "Be fearful when others are greedy, and greedy when others are fearful." Whatever phrase you choose… whenever the "crowd" is....More>>>
It will be 21 years exactly tomorrow since Yahoo, the first-ever Internet tech IPO, made its debut. Since, we’ve seen four other Internet tech IPOs reach a billion-dollar market cap.
That includes Yahoo! Inc. (Nasdaq: YHOO), Amazon.com Inc. (Nasdaq: AMZN), eBay Inc. (Nasdaq: EBAY), Alphabet Inc. (Nasdaq: GOOGL), and Facebook Inc. (Nasdaq: FB) – their combined market caps....More>>>
Migraines affect perhaps a billion people the world over, and it's been three decades since they had a new preventative treatment option. That means there could be enough demand to driveblockbuster sales for a new class of treatments making their way to consumers right now, one of which could co
Shares of Amgen (NASDAQ:AMGN) have earned an average recommendation of “Hold” from the twenty-seven research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and
Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen’s preventive treatment of migraine in adults. It is the first FDA-approved preventive migraine treatment in a new class of drugs, which work by
Ultragenyx (NASDAQ:RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which hap